Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Biogen Lowers FY2025 Adj EPS Guidance from $15.50-$16.00 to $14.50-$15.00 vs $15.80 Est; Sees Sales $9.676B-$9.773B vs $9.686B Est

Author: Benzinga Newsdesk | October 30, 2025 06:06am
Biogen (NASDAQ:BIIB) lowers FY2025 Adj EPS guidance from $15.50-$16.00 to $14.50-$15.00 vs $15.80 analyst estimate. sees sales of $9.676 billion-$9.773 billion vs $9.686 billion analyst estimate.

Posted In: BIIB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist